Proposed roadmap for regulatory leadership to support the inclusion of pregnant and lactating women in clinical trials in African countries

Introduction

The use of medicines during pregnancy and lactation is often necessary, yet around 89% of drug labels do not include human pregnancy data and under 5% contain human lactation data.1 Pregnant and lactating women are often excluded from clinical trials.1–3 Clinical recommendations are almost always derived from non-pregnant, non-lactating adults. Foetal and infant safety are inferred from pre-clinical data. Evidence during pregnancy and lactation usually comes from limited post-approval reports or studies, typically taking a decade or more to validate.4 Women and healthcare providers must therefore make key clinical decisions in the absence of sufficient evidence. This exposes women, foetuses and infants to unquantified risks of treatment and lack of access to the expected benefits of treatment with essential medicines.

These persistent evidence gaps stem from historical ethical frameworks focusing exclusively on fear and risks, emphasising pregnant…
This post was originally published on https://bmjopen.bmj.com